Biomni is a general-purpose biomedical AI agent that autonomously executes complex research workflows across diverse biomedical domains.
This page explains what Biomni is, who should use it, and why it may be the right agent for your workflow.
Biomni is a general-purpose AI research assistant for biomedicine. It can help scientists plan and run complex research workflows across many areas of biology and medicine by combining literature/tool retrieval, reasoning, and code execution. Instead of relying on fixed templates, Biomni can assemble multi-step analyses dynamically, making it useful for tasks such as gene prioritization, drug repurposing, rare disease investigation, microbiome analysis, and protocol generation from real-world biomedical data.
QUESTION
🧬 For chronic myeloid leukemia (CML), return: 1) the hallmark fusion gene, 2) the chromosome translocation, 3) the first FDA-approved targeted drug for CML and its first approval year.
EXPECTED ANSWER
Fusion gene: BCR-ABL1 Translocation: t(9;22) (Philadelphia chromosome) First targeted drug: imatinib (Gleevec) FDA, first approval year: 2001
QUESTION
🦠 Create a mechanism-to-treatment summary for Methicillin-resistant Staphylococcus aureus (MRSA): 1) resistance gene, 2) altered protein target, 3) why most beta-lactams fail, 4) one beta-lactam that can still treat MRSA.
EXPECTED ANSWER
Resistance gene: mecA Altered target: PBP2a (penicillin-binding protein 2a) Failure reason: PBP2a has low affinity for most beta-lactam antibiotics Active beta-lactam: ceftaroline